文献速递冠心病血脂与心血管预防

前列腺癌雄激素剥夺治疗后冠状动脉斑块进展的随机临床试验

Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2026-01-01

本开放标签随机临床试验在4家中心纳入65例无转移性前列腺癌、接受盆腔放疗联合至少6个月ADT的男性,1:1随机接受GnRH激动剂亮丙瑞林或GnRH拮抗剂瑞格列克。治疗12个月后,亮丙瑞林组冠状动脉总斑块体积和非钙化斑块体积增加显著大于瑞格列克组,钙化斑块与低衰减斑块体积变化无显著差异。

要点

  • 在局部前列腺癌放疗联合ADT的男性中,亮丙瑞林较瑞格列克与12个月冠状动脉总斑块体积更大幅增加相关。
  • 斑块进展主要由非钙化斑块体积增加驱动,钙化斑块与低衰减斑块体积变化两组间无显著差异。
  • 该差异可能解释ADT相关心血管风险,提示选择GnRH拮抗剂或加强斑块监测的潜在价值。

核心结论

  • 在局部前列腺癌接受放疗联合ADT的男性中,GnRH激动剂亮丙瑞林较GnRH拮抗剂瑞格列克与12个月内更明显的冠状动脉斑块进展相关。
  • 该变化由非钙化斑块体积增加驱动,可能介导ADT相关心血管风险。

研究设计与样本

  • 开放标签随机临床试验,在佐治亚州亚特兰大单一家学术机构附属的4家中心开展。
  • 纳入无转移性前列腺癌、既往未接受ADT、接受盆腔放疗且ADT疗程≥6个月的男性,1:1随机分配至亮丙瑞林或瑞格列克。
  • 共65例入组,62例(每组31例)完成全部研究程序用于分析;平均(SD)年龄68.5(8.5)岁,35/62(56%)使用他汀。
  • 主要终点为基线及ADT启动后12个月冠状动脉CT血管造影测量的冠状动脉总斑块体积(TPV)变化。

主要发现

  • 校正基线斑块体积、年龄和他汀使用后,亮丙瑞林较瑞格列克与12个月TPV增加更大相关(估计差值+68.9 mm3;95%CI 23.2-114.5 mm3;P=.02)。
  • 校正后亮丙瑞林较瑞格列克与12个月非钙化斑块体积(NCPV)增加更大相关(+64.5 mm3;95%CI 31.6-97.3 mm3;P=.004)。
  • 两组12个月钙化斑块体积(CPV)和低衰减斑块体积(LAPV)变化无显著差异。

关键数值与推荐

  • 主要终点:冠状动脉总斑块体积(TPV)12个月变化,亮丙瑞林vs瑞格列克估计差值+68.9 mm3(95%CI 23.2-114.5 mm3;P=.02)。
  • 次要终点:非钙化斑块体积(NCPV)12个月变化,估计差值+64.5 mm3(95%CI 31.6-97.3 mm3;P=.004)。
  • CPV与LAPV的12个月变化两组间无显著差异。
  • ADT疗程为6个月或更长,随机分组为GnRH激动剂亮丙瑞林或GnRH拮抗剂瑞格列克。

临床怎么用

  • 对需接受ADT的前列腺癌患者,处方GnRH激动剂时应意识到其可能较拮抗剂更促进冠状动脉非钙化斑块进展。
  • 可与肿瘤科协作评估ADT类型选择,尤其对已有心血管风险或他汀治疗中的患者。
  • 对接受GnRH激动剂ADT者,可考虑加强心血管危险因素管理与冠状动脉斑块评估。
  • 本研究样本量小、随访12个月,结果需更大规模研究验证后方可改变常规处方决策。

局限性

  • 开放标签设计,未设盲。
  • 样本量小:65例入组、62例完成分析。
  • 随访仅12个月,无法评估长期临床心血管事件。
  • 单一家学术机构附属的4家中心开展,外推性受限。
  • 主要终点为影像学斑块体积变化,非硬性心血管终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Androgen deprivation therapy (ADT) for men with prostate cancer (PCa) is associated with cardiovascular (CV) morbidity, yet the biological basis remains unclear. Recent studies have yielded conflicting results regarding the CV safety of gonadotropin-releasing hormone (GnRH) agonists vs antagonists. OBJECTIVE: To test the hypothesis that ADT is associated with accelerated coronary atherosclerosis and is more prominent with a GnRH agonist compared with a GnRH antagonist. DESIGN, SETTING, AND PARTICIPANTS: This open-label randomized clinical trial was conducted at 4 centers affiliated with a single academic institution in Atlanta, Georgia. Participants were men with nonmetastatic PCa without prior ADT exposure receiving pelvic radiotherapy with ADT of 6 months duration or longer. Patients were randomly assigned 1:1 to either the GnRH agonist leuprolide or the GnRH antagonist relugolix. Trial enrollment was completed between June 16, 2022, and March 6, 2024. Data analysis was completed between March 31, 2025, and June 23, 2025. INTERVENTION: Pelvic radiotherapy plus either GnRH agonist leuprolide or GnRH antagonist relugolix. MAIN OUTCOMES AND MEASURES: The primary end point was change in coronary artery total plaque volume (TPV), measured by coronary computed tomographic angiography completed at baseline and 12 months after ADT initiation. The secondary end point was change in coronary artery noncalcified plaque volume (NCPV). Other outcome measures included change in calcified plaque volume (CPV) and low-attenuation plaque volume (LAPV). RESULTS: Of 65 men enrolled, 62 (31 in each arm) completed all study procedures for analysis. Mean (SD) age was 68.5 (8.5) years, and 35 of 62 participants (56%) were taking statins. Compared with relugolix, leuprolide was associated with a significantly greater 12-month increase in TPV (estimated difference, +68.9 mm3; 95% CI, 23.2-114.5 mm3; P = .02) and NCPV (+64.5 mm3; 95% CI, 31.6-97.3 mm3; P = .004) after adjustment for baseline plaque volume, age, and statin use. There was no significant difference in 12-month change in CPV or LAPV between patients treated with leuprolide vs relugolix. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial in men with localized PCa treated with radiation plus ADT, the GnRH agonist leuprolide was associated with greater coronary plaque progression within 12 months compared with the GnRH antagonist relugolix. This change was driven by an increase in noncalcified plaque volume and may be mediating ADT-associated CV risk. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05320406.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Patel SA, Yadalam AK, van Assen M, et al. Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41706486. doi:10.1001/jamacardio.2025.5586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。